The Progression-Free Survival Of The First-Line Egfr-Tki Is A Strong Prognosticator Of The Second-Line Osimertinib In Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr-T790m Mutation: A Real-World Study
ANNALS OF ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要